
First published in the *Government Gazette*, Electronic Edition, on 28 April 2017 at 5 pm.

No. S 194

MISUSE OF DRUGS ACT (CHAPTER 185)

MISUSE OF DRUGS ACT (AMENDMENT OF FIRST AND FIFTH SCHEDULES) ORDER 2017

In exercise of the powers conferred by sections 58A and 59 of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Order:

Citation and commencement

1. This Order is the Misuse of Drugs Act (Amendment of First and Fifth Schedules) Order 2017 and comes into operation on 1 May 2017.

Amendment of Part I of First Schedule

2. Part I of the First Schedule to the Misuse of Drugs Act is amended —

(a) by deleting item (8) of paragraph 1;

(b) by deleting item (20) of paragraph 1 and substituting the following item:

“(20) 2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine (also known as 4-bromo-2,5-dimethoxyphenethylamine or 2C-B) and its bromo and dimethoxy positional isomers in the phenyl ring”;

(c) by deleting items (44) and (45) of paragraph 1 and substituting the following items:

“(44) 2,5-Dimethoxy-4,α-dimethylphenethylamine (also known as 2-amino-1-(2,5-dimethoxy-4-methyl)phenylpropane or DOM)

(45) 2,5-Dimethoxy-α-methylphenethylamine (also known as 2,5-Dimethoxyamphetamine) and its dimethoxy positional isomers in the phenyl ring”;

(d) by deleting item (86) of paragraph 1 and substituting the following item:

“(86) p-Methoxy- α -methylphenethylamine (also known as 4-methoxyamphetamine or para-methoxyamphetamine) and its methoxy positional isomers in the phenyl ring”;

(e) by inserting, immediately after item (7) of paragraph 7, the following item:

“(7A) Butyryl fentanyl (also known as butyrfentanyl)”;

(f) by deleting items (1) and (2) of paragraph 16 and substituting the following items:

“(1) 1-(1,3-Benzodioxol-5-yl)-2-(benzylamino)propan-1-one (also known as 3,4-Methylenedioxy-N-benzylcathinone or BMDP)

(1A) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)-1-propanone (also known as bk-MDDMA)

(2) 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)propan-1-one (also known as ethylone or 3,4-Methylenedioxy-N-ethylcathinone or bk-MDEA or MDEC)”;

(g) by deleting item (8A) of paragraph 16 and substituting the following items:

“(8A) 2-(Benzylamino)-1-(4-methylphenyl)propan-1-one (also known as Benzedrone)

(8AA) 1-(4-Bromophenyl)-2-(methylamino)propan-1-one (also known as 4-Bromomethcathinone or Brephedrone or 4-BMC)”;

(h) by inserting, immediately after item (8B) of paragraph 16, the following item:

“(8C) 2-(Diethylamino)-1-phenyl-1-propanone (also known as amfepramone or diethylpropion or diethylcathinone)”;

(i) by deleting item (10A) of paragraph 16 and substituting the following items:

“(10A) 2-(Ethylamino)-1-(4-ethylphenyl)propan-1-one (also known as 4-Ethylethcathinone)

(10B) 2-(Ethylamino)-1-(4-fluorophenyl)propan-1-one (also known as 4-Fluoroethcathinone or 4-FEC)”;

(j) by inserting, immediately after item (17) of paragraph 16, the following item:

“(17A) 2-(Methylamino)-1-(4-methylphenyl)butan-1-one (also known as 4-Methylbuphedrone or 4-Me-MABP)”;

(k) by deleting item (19) of paragraph 16 and substituting the following item:

“(19) 2-(Methylamino)-1-phenylpentan-1-one (also known as pentedrone or α -Methylaminovalerophenone)”;

(l) by inserting, immediately after item (22) of paragraph 16, the following item:

“(22A) 1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one (also known as 4-Methyl- α -pyrrolidinohexanophenone or MPHP)”;

(m) by inserting, immediately after item (23) of paragraph 16, the following item:

“(23A) 1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)propan-1-one (also known as 4-Methyl- α -pyrrolidinopropiophenone or 4-MePPP)”;

(n) by deleting item (2B) of paragraph 18 and substituting the following item:

“(2B) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as MAB-CHMINACA or ADB-CHMINACA)”;

(o) by deleting items (2J) and (2K) of paragraph 18 and substituting the following items:

“(2J) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also

known as PX-2 or 5-Fluoro-APP-PINACA) and its fluoro positional isomers in the pentyl group

(2K) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (also known as PX-1 or 5-Fluoro-APP-PICA) and its fluoro positional isomers in the pentyl group”;

(p) by inserting, immediately after item (10A) of paragraph 18, the following item:

“(10B) 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-47700) and its dichloro positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring”;

(q) by inserting, immediately after item (20) of paragraph 18, the following item:

“(20A) 5-Fluoropent-1-yl-N-naphthalen-1-yl-1H-indole-3-carboxamide (also known as CBM-2201, 5-Fluoro-NNEI, 5F-NNEI or MN-24F) and its fluoro positional isomers in the pentyl group”;

(r) by deleting item (26) of paragraph 18 and substituting the following item:

“(26) 9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol (for example HU-210, HU-211)”;

(s) by deleting item (28C) of paragraph 18 and substituting the following items:

“(28C) Methyl 2-[1-(cyclohexylmethyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl N-{{[1-(cyclohexylmethyl)-1H-indol-3-yl]carbonyl}}-3-methyl-L-valinate or MDMA-CHMICA)

(28D) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as 5-Fluoro-AMB) and its fluoro positional isomers in the pentyl group”; and

(t) by deleting item (36) of paragraph 18 and substituting the following items:

- “(36) Naphthalen-1-yl 5-fluoropent-1-yl-1H-indole-3-carboxylate (also known as NM-2201 or CBL-2201) and its fluoro positional isomers in the pentyl group
- (36A) Naphthalen-1-yl(4-pentyloxynaphthalen-1-yl) methanone (also known as CB-13)
- (36B) Naphthalen-1-yl[1-(pent-1-yl)-1H-indazol-3-yl] methanone (also known as THJ-018)”.

Deletion and substitution of Fifth Schedule

3. The Fifth Schedule to the Misuse of Drugs Act is deleted and the following Schedule substituted therefor:

“FIFTH SCHEDULE

Sections 24, 26, 27, 32 and 58A

TEMPORARILY LISTED DRUGS

1. The following compounds, including any salt or stereoisomeric form of such compounds, and any preparation or product containing such compounds:

- (1) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as ADB-FUBINACA) and its fluoro positional isomers in the phenyl ring
- (2) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (also known as ADBICA)
- (3) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as PX-3 or APP-CHMINACA)
- (4) 1-Benzyl-4-methylpiperazine (also known as methylbenzylpiperazine or MBZP)
- (5) 2-Bis(4-fluorophenyl)methylsulfinyl-N-methylacetamide (also known as N-methyl-4,4-difluoromodafinil or modafiendz) and its fluoro positional isomers in the phenyl rings
- (6) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (also known as 2C-C) and its chloro and dimethoxy positional isomers in the phenyl ring

-
-
- (7) Methyl 2-[1-(4-fluorobenzyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as MDMB-FUBINACA) and its fluoro positional isomers in the phenyl ring
 - (8) 4-Fluoromethylphenidate and its fluoro positional isomers in the phenyl ring
 - (9) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as 5-Fluoro-MDMB-PINACA or 5-Fluoro-ADB) and its fluoro positional isomers in the pentyl group”.

Made on 28 April 2017.

LEO YIP
*Permanent Secretary,
Ministry of Home Affairs,
Singapore.*

[MHA 112/2/0049; AG/LEGIS/SL/185/2015/1 Vol. 2]